These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

275 related items for PubMed ID: 162484

  • 1. Activation of the alternative complement pathway.
    Fearon DT.
    CRC Crit Rev Immunol; 1979 Nov; 1(1):1-32. PubMed ID: 162484
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A circulating inhibitor of fluid-phase amplification. C3 convertase formation in systemic lupus erythematosus.
    Waldo FB, Forristal J, Beischel L, West CD.
    J Clin Invest; 1985 Jun; 75(6):1786-95. PubMed ID: 3159752
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?
    Harrison RA.
    Semin Immunopathol; 2018 Jan; 40(1):15-35. PubMed ID: 29167939
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Interaction of C3b(2)--IgG complexes with complement proteins properdin, factor B and factor H: implications for amplification.
    Jelezarova E, Vogt A, Lutz HU.
    Biochem J; 2000 Jul 01; 349(Pt 1):217-23. PubMed ID: 10861231
    [Abstract] [Full Text] [Related]

  • 13. Sensitive and specific assays for C3 nephritic factors clarify mechanisms underlying complement dysregulation.
    Paixão-Cavalcante D, López-Trascasa M, Skattum L, Giclas PC, Goodship TH, de Córdoba SR, Truedsson L, Morgan BP, Harris CL.
    Kidney Int; 2012 Nov 01; 82(10):1084-92. PubMed ID: 22854646
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
    Farries TC, Lachmann PJ, Harrison RA.
    Biochem J; 1988 May 15; 252(1):47-54. PubMed ID: 3421908
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Residual hemolytic and proteolytic activity expressed by Bb after decay-dissociation of C3b,Bb.
    Fishelson Z, Müller-Eberhard HJ.
    J Immunol; 1984 Mar 15; 132(3):1425-9. PubMed ID: 6229580
    [Abstract] [Full Text] [Related]

  • 18. [Alternative complement pathway (author's transl)].
    Kazatchkine M, Nydegger U, Fearon DT.
    Nouv Presse Med; 1979 Jun 09; 8(26):2187-94. PubMed ID: 382108
    [Abstract] [Full Text] [Related]

  • 19. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
    Parker CJ, Baker PJ, Rosse WF.
    J Clin Invest; 1982 Feb 09; 69(2):337-46. PubMed ID: 6915939
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.